Page 116 - Read Online

Page 28 of 34 West et al. Rare Dis Orphan Drugs J 2024;3:22 https://dx.doi.org/10.20517/rdodj.2023.61

patients with Fabry disease: a multicenter Fabry registry study. Mol Genet Genom Med 2018;6:492-503. DOI PubMed PMC
13. Oder D, Liu D, Hu K, et al. α-galactosidase a genotype N215S Induces a specific cardiac variant of Fabry disease. Circ Cardiovasc
Genet 2017;10:e001691. DOI
14. Lavalle L, Thomas AS, Beaton B, et al. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S
mutation. PLoS One 2018;13:e0193550. DOI PubMed PMC
15. Hsu TR, Sung SH, Chang FP, et al. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese
later-onset Fabry mutation (IVS4 + 919G > A). Orphanet J Rare Dis 2014;9:96. DOI PubMed PMC
16. Lin HY, Huang CH, Yu HC, et al. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation
(IVS4 + 919G→A). J Inherit Metab Dis 2010;33:619-24. DOI
17. Lukas J, Scalia S, Eichler S, et al. Functional and clinical consequences of novel α-galactosidase a mutations in Fabry disease. Hum
Mutat 2016;37:43-51. DOI
18. Selvarajah M, Nicholls K, Hewitson TD, Becker GJ. Targeted urine microscopy in anderson-Fabry disease: a cheap, sensitive and
specific diagnostic technique. Nephrol Dial Transplant 2011;26:3195-202. DOI PubMed
19. Fall B, Scott CR, Mauer M, et al. Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical
severity of Fabry nephropathy. PLoS One 2016;11:e0168346. DOI PubMed PMC
20. Mignani R, Preda P, Granata A, et al. Isolated microalbuminuria as the first clinical presentation of Fabry disease in an adult
heterozygous female. NDT Plus 2009;2:455-7. DOI PubMed PMC
21. Marchel D, Trachtman H, Larkina M, et al. The significance of hematuria in podocytopathies. Clin J Am Soc Nephrol 2023;19:56-66.
DOI PubMed PMC
22. Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol
Dial Transplant 2018;33:318-23. DOI
23. Wornell P, Dyack S, Crocker J, Yu W, Acott P. Fabry disease and nephrogenic diabetes insipidus. Pediatr Nephrol 2006;21:1185-8.
DOI PubMed
24. Sessa A, Meroni M, Battini G, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 2001;24:66-70. DOI
25. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and
cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009;24:2102-11. DOI PubMed PMC
26. West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132-9.
DOI PubMed PMC
27. Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G; European FOS Investigators. Enzyme replacement
therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 2006;66:77-84. PubMed
28. Wanner C, Feldt-Rasmussen U, Jovanovic A, et al. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry
patients: a pre-treatment vs. post-treatment analysis. ESC Heart Fail 2020;7:825-34. DOI PubMed PMC
29. Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc
Nephrol 2017;28:1631-41. DOI PubMed PMC
30. Arends M, Biegstraaten M, Hughes DA, et al. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry
disease: analysis of prognostic factors. PLoS One 2017;12:e0182379. DOI PubMed PMC
31. Drechsler C, Schmiedeke B, Niemann M, et al. Potential role of vitamin D deficiency on Fabry cardiomyopathy. J Inherit Metab Dis
2013;37:289-95. DOI PubMed PMC
32. Chiorean A, Lyn N, Kabadi S, et al. Cluster analysis of kidney function decline among males with Fabry disease in a large United
States electronic health records database. Nephrol Dial Transplant 2023;38:2350-7. DOI PubMed PMC
33. Sharma A, Sartori M, Zaragoza JJ, et al. Fabry’s disease: an example of cardiorenal syndrome type 5. Heart Fail Rev 2015;20:689-
708. DOI
34. Siegenthaler M, Huynh-Do U, Krayenbuehl P, et al. Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry
disease in a long-term follow-up. Int J Cardiol 2017;249:261-7. DOI
35. Clements JN. Development and current role of sodium glucose cotransporter inhibition in cardiorenal metabolic syndrome. J
Cardiovasc Pharmacol 2022;79:593-604. DOI PubMed
36. Bird S, Hadjimichael E, Mehta A, Ramaswami U, Hughes D. Fabry disease and incidence of cancer. Orphanet J Rare Dis
2017;12:150. DOI PubMed PMC
37. Pagni F, Pieruzzi F, Zannella S, et al. Possible pathogenetic relationship between Fabry disease and renal cell carcinoma. Am J
Nephrol 2012;36:537-41. DOI
38. Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of
female carriers. Clin Chim Acta 2005;353:201-3. DOI PubMed
39. Ferreira S, Ortiz A, Germain DP, et al. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype:
data from individual patients and family studies. Mol Genet Metab 2015;114:248-258. DOI PubMed PMC
40. Cerón-Rodríguez M, Ramón-García G, Barajas-Colón E, Franco-Álvarez I, Salgado-Loza JL. Renal globotriaosylceramide deposits
for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T/p.Arg118Cys: a family study. Mol Genet Genom Med
2019;7:e981. DOI PubMed PMC
41. Lenders M, Weidemann F, Kurschat C, et al. Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare
Dis 2016;11:54. DOI PubMed PMC